Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depressionJournal of Affective Disorders · 2026-11-01The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysisJournal of Affective Disorders · 2026-08-01Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal IdeationThe Journal of Clinical Psychiatry · 2026-05-13Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].Journal of affective disorders · 2026-01-15Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study.Journal of affective disorders · 2025-11-15630. Synthetic Psilocybin (COMP360) for Chronic Active Suicidal Ideation: An Open-Label StudyBiological Psychiatry · 2025-04-09The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.Journal of affective disorders · 2025-03-01A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.Psychedelic medicine (New Rochelle, N.Y.) · 2025-03-01Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.Journal of affective disorders · 2025-01-15Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.The American journal of psychiatry · 2025-01-01Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.JAMA psychiatry · 2024-06-01Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety-Reply.JAMA psychiatry · 2024-06-01New evidence for flexible psilocybin dosing in patients with treatment-resistant depression.Med (New York, N.Y.) · 2024-03-08Psychedelics, With a Focus on Psilocybin: Issues for the Clinician.Journal of psychiatric practice · 2023-09-01Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.Journal of affective disorders · 2023-04-1496. An Open Label Study of Synthetic Psilocybin in Bipolar Type II DepressionBiological Psychiatry · 2023-04-10Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation.Journal of affective disorders · 2023-04-01Assessing potential of psilocybin for depressive disorders.Expert opinion on investigational drugs · 2023-01-01Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.The New England journal of medicine · 2022-11-03The Emerging Field of Psychedelic Psychotherapy.Current psychiatry reports · 2022-10-01Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language ProcessingPsyArXiv · 2022-09-30Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language ProcessingPsyArXiv · 2022-09-30P388. Open Label Psilocybin Administration in Severely Treatment Resistant DepressionBiological Psychiatry · 2022-04-27The efficacy of COMP360 psilocybin therapy in treatment-resistant depression: exploratory results from a phase IIb randomised controlled trialNeuroscience Applied · 2022-01-01The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trialNeuroscience Applied · 2022-01-01